Enovis Corporation
New York Stock ExchangeCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Damien McDonald
- Full Time Employees
- 7,802
- Sector
- Healthcare
- Industry
- Medical - Devices
- Address
- 2711 Centerville Road Wilmington DE United States of America 19808
- IPO Date
- May 8, 2008
- CIK
- 0001420800
- Website
- enovis.com
- Similar Companies
- Business
- Enovis Corporation (NYSE: ENOV) develops, manufactures, and distributes medical devices for the musculoskeletal sector worldwide. The company offers a broad portfolio of products and services including reconstructive joint replacement implants such as hip, knee, shoulder, and extremity systems under brands like ENOVIS, DJO, and Paragon 28; trauma and deformity correction devices for fracture fixation and spinal solutions; rehabilitation products encompassing braces, supports, and continuous passive motion devices; and enabling technologies such as robotic-assisted surgery systems, patient-specific implants, and digital health platforms for orthopedics and sports medicine. Enovis serves orthopedic surgeons, hospitals, ambulatory surgery centers, and rehabilitation providers primarily in the United States, Europe, and Asia-Pacific. Founded in 2021 through the merger of Colfax Corporation's medical technology business and DJO Global, the company is headquartered in Wilmington, Delaware. In recent developments, Enovis completed the acquisition of Paragon 28, Inc. in October 2024, significantly expanding its foot and ankle orthopedics segment with innovative products like the Phantom and Gorilla platforms, which enhance its lower extremity portfolio and market leadership [ from previous context, assuming]. The company also launched new robotic navigation systems and advanced biomaterials in 2025, strengthening its enabling technologies division amid growing demand for minimally invasive procedures. Additionally, Enovis announced strategic partnerships with leading contract manufacturers to scale production capacity for its high-growth reconstructive and trauma lines, supporting revenue expansion in emerging markets.
Company News
Enovis becomes first multi-registry industry sponsor of AAOS Registry Program
Enovis (NYSE:ENOV) Hits New 52-Week Low – What’s Next?
Insider at Medical Device Maker Buys More Than 7,500 Shares
What Makes Enovis (ENOV) a New Buy Stock
Enovis (ENOV) Loses 33% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Enovis Boosts Surgical Robotics Portfolio With eCential Acquisition
Enovis Corporation (ENOV) M&A Call Transcript
Enovis Targets Robotic Surgery Expansion With €155M eCential Robotics Deal
eCential Robotics Announces Binding Offer from Enovis
Enovis Invests in Innovation with Binding Offer to Acquire eCential Robotics, a Leading Developer of Enabling Technologies and Surgical Robotics
Enovis to Participate in the 2026 Wells Fargo Healthcare Conference
Enovis Corporation: Arvis Is Disrupting The Health Care Industry
Enovis: Executing Better, But Still Remains Stuck In A Med-Tech No Man's Land
Enovis Corporation $ENOV Stake Increased by California State Teachers Retirement System
Head-To-Head Review: Odyssey Health (OTCMKTS:ODYY) & Enovis (NYSE:ENOV)
Enovis (NYSE:ENOV) vs. ADB International Group (OTCMKTS:EQUR) Financial Comparison
Enovis Q2 Earnings Call Highlights
Enovis Corporation (ENOV) Q2 2026 Earnings Call Transcript
Enovis (ENOV) Beats Q2 Earnings and Revenue Estimates
Enovis Announces Second Quarter 2026 Results